Counts of positive, neutral, and negative news items. Not a price chart.
Informational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
The items moving the net sentiment the most, by direction and influence.
GSK Secures FDA Approval for Utebzi, Momelotinib Gains Orphan Tag: Boost for Pharma Pipeline
Direct news · High influence · Long term
US FDA Approves GSK Antibiotic for Drug-Resistant UTIs: Pharmaceutical Stock in Focus
Direct news · High influence · Long term
GSK Boosts Oncology Pipeline with $11 Billion Nuvalent Deal: Pharmaceutical Stock in Focus
Direct news · High influence · Long term
GSK Acquires Nuvalent for $10.6 Billion, Boosting Oncology Pipeline
Direct news · High influence · Long term
GSK Expands Sino Bio Partnership in $4.5 Billion Inhaler Deal
Direct news · Medium influence · Long term
Macro, commodity, FX and regulatory forces that moved GSK in this range, with the stories behind each.
No indirect-driver news for GSK in this range.
Also monitored for GSK (no news in this range): US Fed / global rates & risk, UK Budget / fiscal & tax, Drug approvals & trial outcomes, Sterling (GBP).
Sign up free to track GSK, unlock full history and the complete driver breakdown, and get alerts when sentiment shifts.
Track GSK for freeInformational only, not investment advice. Sentiment reflects news exposure, not a buy/sell recommendation or price forecast. Do your own research and consult a licensed professional.
GSK Acquires Nuvalent for $10.6 Billion in Major Oncology Expansion
